The European Medicines Agency (EMA) announced on Tuesday 20 July that it had begun a rolling review of a new vaccine against Covid-19: Vidprevtyn, developed by the French pharmaceutical company Sanofi Pasteur.
“It is a protein-based vaccine that contains a laboratory-grown version of the spike protein found on the surface of SARS-CoV-2”, the EMA said.
Once the vaccine has been administered, the immune system of the vaccinated person should identify the spike protein as foreign, produce...